204 related articles for article (PubMed ID: 14600205)
1. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment.
Krauss J; Arndt MA; Martin AC; Liu H; Rybak SM
Protein Eng; 2003 Oct; 16(10):753-9. PubMed ID: 14600205
[TBL] [Abstract][Full Text] [Related]
2. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
Ho M; Kreitman RJ; Onda M; Pastan I
J Biol Chem; 2005 Jan; 280(1):607-17. PubMed ID: 15491997
[TBL] [Abstract][Full Text] [Related]
4. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
Krauss J; Arndt MA; Vu BK; Newton DL; Seeber S; Rybak SM
Biochem Biophys Res Commun; 2005 Jun; 331(2):595-602. PubMed ID: 15850802
[TBL] [Abstract][Full Text] [Related]
5. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
7. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
[TBL] [Abstract][Full Text] [Related]
8. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.
Engel P; Wagner N; Miller AS; Tedder TF
J Exp Med; 1995 Apr; 181(4):1581-6. PubMed ID: 7535343
[TBL] [Abstract][Full Text] [Related]
9. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
10. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
11. A novel tumor-specific human single-chain Fv selected from an active specific immunotherapy phage display library.
Hall BL; Boroughs J; Kobrin BJ
Immunotechnology; 1998 Oct; 4(2):127-40. PubMed ID: 9853954
[TBL] [Abstract][Full Text] [Related]
12. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
14. Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.
Rothe A; Klimka A; Tur MK; Pfitzner T; Huhn M; Sasse S; Mallmann P; Engert A; Barth S
Int J Mol Med; 2004 Oct; 14(4):729-35. PubMed ID: 15375609
[TBL] [Abstract][Full Text] [Related]
15. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes.
de Kruif J; Storm G; van Bloois L; Logtenberg T
FEBS Lett; 1996 Dec; 399(3):232-6. PubMed ID: 8985152
[TBL] [Abstract][Full Text] [Related]
16. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
17. Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.
Krauss J; Arndt MA; Vu BK; Newton DL; Rybak SM
Br J Haematol; 2005 Mar; 128(5):602-9. PubMed ID: 15725080
[TBL] [Abstract][Full Text] [Related]
18. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
[TBL] [Abstract][Full Text] [Related]
19. The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries.
MacKenzie R; To R
J Immunol Methods; 1998 Nov; 220(1-2):39-49. PubMed ID: 9839924
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
